Home » Stocks » PSTX

Poseida Therapeutics, Inc. (PSTX)

Stock Price: $8.55 USD -0.35 (-3.93%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 531.03M
Revenue (ttm) n/a
Net Income (ttm) -129.78M
Shares Out 36.00M
EPS (ttm) -3.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $8.55
Previous Close $8.90
Change ($) -0.35
Change (%) -3.93%
Day's Open 8.93
Day's Range 8.38 - 8.90
Day's Volume 113,492
52-Week Range 7.63 - 17.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

1 week ago - PRNewsWire

SAN DIEGO, March 23, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...

3 weeks ago - PRNewsWire

SAN DIEGO, March 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...

1 month ago - PRNewsWire

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biophar...

Other stocks mentioned: PRAH, SLRX, SNSS
1 month ago - Benzinga

The biotech reported pipeline progress at its virtual R&D Day.

1 month ago - The Motley Fool

SAN DIEGO, Dec. 5, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell a...

4 months ago - PRNewsWire

SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologi...

5 months ago - PRNewsWire

SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technolo...

6 months ago - PRNewsWire

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc.

7 months ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $PSTX #PSTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc.

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $PSTX #PSTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc.

7 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GNUS #ClassAction--Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated secu...

7 months ago - Business Wire

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc.

7 months ago - PRNewsWire

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Poseida Therapeutics, Inc.

7 months ago - PRNewsWire

Poseida Therapeutics Inc. (NASDAQ: PSTX) stock dropped about 34.5% in the after-hours trading on Monday, after a patient died in a prostate cancer drug trial, according to a filing the company made with...

7 months ago - Benzinga

Poseida Therapeutics Inc. shares dropped in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patient death.

8 months ago - Market Watch

Poseida Therapeutics Inc. PSTX, -0.76% shares were halted in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patien...

8 months ago - Market Watch

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: BBBY, AKRO, AZZ, GSK, NKTX, PRSP, TSE ...
8 months ago - Benzinga

Shares of Poseida Therapeutics Inc. PSTX, 0.00% kicked off their public life with a gain, after the biopharmaceutical company's initial public offering priced at the top of the expected range, but those...

9 months ago - Market Watch

About PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat rel... [Read more...]

Industry
Biotechnology
IPO Date
Jul 10, 2020
CEO
Eric Ostertag
Employees
206
Stock Exchange
NASDAQ
Ticker Symbol
PSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PSTX stock is "Strong Buy." The 12-month stock price forecast is 25.00, which is an increase of 192.40% from the latest price.

Price Target
$25.00
(192.40% upside)
Analyst Consensus: Strong Buy